Aumolertinib combined with targeting ETV4 in the treatment of non-small cell lung cancer

Journal of Thoracic Disease 2026 Open access

Read full text
Authors: Yingjie Lu, Dongfang Tang, Huibiao Zhang, Zhengyao Yang, Jing WANG, Wen Gao
DOI: 10.21037/jtd-2025-aw-2071
Cited by: 1

Abstract

Background: -mutant non-small cell lung cancer (NSCLC), but acquired resistance remains a major challenge. Third-generation EGFR-TKIs like aumolertinib show efficacy, yet their molecular mechanisms and sensitivity optimization need further exploration. The aim of this study is to enhance the efficacy of aumolertinib in the treatment of NSCLC. Methods: ), or their combination. Results: . Conclusions: is a potential therapeutic co-target, serving as a treatment strategy to prevent the acquired resistance induced by aumolertinib.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Lung Cancer Research Studies

Publication details

Journal / source
Journal of Thoracic Disease
Publisher
AME Publishing Company
Volume
18
Issue
2
Pages
125–125
Publication date
1 February 2026
Language
EN